| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca32fd2a44fd326ffd027a75a57bd13f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e664314069a62de61353d66f47ef3365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09e7f812e38c0a62443883f69929ec88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1fdcfdbe580c5e581e0aa0cfa3e87f17 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16222 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16 |
| filingDate |
2000-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff88c7f984f0e11366cec9d39ad3ef4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0f0d69153ca9a2377199a838e5f0ae7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efb6d5af3dcf74d442cf3e5e8675bf45 |
| publicationDate |
2002-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0127291-A9 |
| titleOfInvention |
Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| abstract |
H-2 class I negative, HLA-A2.1 transgenic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumour-associated CTL epitopes and HIV 1-derived epitopes. A hierarchy was established among these epitopic peptides injected into mice in IFA which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. A tyrosine substitution in position 1 of the HIV 1-derived epitopic peptides, which increases both their affinity for and their HLA-A2.1 molecule stabilizing capacity, was introduced in a significant proportion of them. DNA immunizations were performed using a construct comprising nucleic acids encoding the epitopes inserted into the pre-S2 segment of the hepatitis B middle glycoprotein. CTL responses against most of the inserted epitopes could be elicited simultaneously in a single animal. |
| priorityDate |
1999-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |